Find Answers Fast.

Intelligently search across the largest database of BioPharma industry documents. Benefit from instant AI Answers with citations linking directly to reference passages.



Provide a summary of Lilly's likely BD priorities based on their past few earnings calls?




Eli Lilly And Co (LLY) - Q1 2024 Earnings Call

Earnings Call Transcript


Based on analysis of Eli Lilly and Company's recent earnings calls, the company's business development (BD) priorities can be summarized as follows:

1. Expansion Through Strategic Acquisitions

Lilly has demonstrated a clear focus on expanding its pipeline and capabilities through targeted acquisitions of clinical-stage companies and technologies. For instance, recent acquisitions include DICE Therapeutics, Versanis Bio, Emergence Therapeutics, Sigilon Therapeutics, and POINT Biopharma. These acquisitions are intended to bolster their Phase 2 portfolio and expand capabilities in areas like radioligand therapies and immuno-oncology [1].

2. Focus on Innovative Therapies for Key Therapeutic Areas

Lilly continues to prioritize treatment areas such as oncology, immunology, diabetes, and neuroscience: - Oncology: The acquisition of POINT Biopharma highlights their interest in next-generation radioligand therapies for cancer[2]. - Diabetes: Innovations in diabetes treatment remain a top priority, with investments in expanding capacities for therapies like Mounjaro (tirzepatide)[1]. - Neuroscience and Immunology: With the recent Phase 1/2 trial for the Otoferlin Gene therapy asset and completed Phase 3 trials for innovative drugs like mirikizumab, Lilly is clearly focused on advancing their offerings in these fields despite facing operational challenges such as manufacturing issues with lebrikizumab's third-party suppliers [1].

AI-enabled search powered by the largest BioPharma specific document database

Updated hourly, with >10 years of history for >1,800 publicly listed BioPharma companies

maven bio

Document Search Results

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells



Press Release


Kite Pharma

PFS is defined as the time from the KITE-718 infusion date to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death from any cause.

Aim Immunotech (AIM) - 8-K Filing Exhibit





Aim Immunotech

The presentation highlights the potential of Ampligen®, a dsRNA/TLR3 agonist, in modulating chemokines to enhance T effector cell infiltration in tumors, particularly in colorectal cancer. Data shows Ampligen's efficacy in improving Teff/Treg ratio across various solid tumors. A recent study in late-stage pancreatic cancer patients demonstrated a significant increase in overall survival with Ampligen monotherapy, leading to FDA clearance for a Phase 2 study. Ampligen also shows promise in ME/CFS and post-COVID chronic fatigue-like conditions. AIM ImmunoTech, the company behind Ampl

ImmunoBiochem Corp.



News Article

Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion ...

AI Search Capabilities

Benefit from the only search engine specifically designed to handle Biopharma search queries.

maven bio

Document Search

Search millions of Biopharma press releases, SEC filings, and earning transcripts

Related to company

Document Type

Start Date


End Date


Powerful BioPharma Filters

A search engine specifically designed to handle BioPharma search queries

maven bio



Give an overview of Allogene. I have a meeting with them tomorrow.




Allogene Therapeutics S-1 Breakdown

SEC Filing


Allogene Therapeutics is a clinical-stage biotechnology company that is pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer[1]. The company is headquartered in South San Francisco and is led by a management team with significant experience in cell therapy. Allogene is focused on developing a pipeline of "off-the-shelf" CAR T cell therapy candidates with the aim of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients[1].

The founders of Allogene, Arie Belldegrun and David Chang, previously sold their first CAR-T company, Kite Pharma, for $12 billion. Following the acquisition of Kite by Gilead, they founded Allogene with a focus on developing allogeneic CAR therapeutics[1]. The company was launched with a strategy to acquire and develop a portfolio of 16 preclinical cell therapy assets from Pfizer, including UCART19, an allogeneic CAR T therapy targeting CD19 currently in Phase 1 development for the treatment of refractory and relapsed acute lymphoblastic leukemia (ALL)[1][4]. This acquisition marked Pfizer’s exit from adoptive cell therapy, but allowed them to retain a 25 percent ownership stake in Allogene[4].

Allogene has made significant progress in its development pipeline, including the initiation of the Phase 1/2 ALPHA clinical trial of ALLO-501, an anti-CD19 AlloCAR T™ product in patients with relapsed/refractory non-Hodgkin lymphoma. The company has also been working on building a state-of-the-art AlloCAR T™ manufacturing facility in Newark, California, and has presented initial Phase 1 data for several of its therapies[4].

In terms of financial milestones, Allogene completed one of the largest Series A financing rounds in biotechnology history, raising $300 million. This was followed by a successful public company debut, raising $372.6 million in gross proceeds in what was the second-largest biotechnology IPO of 2018[4][4].

Comprehensive Coverage

Comb through full text press releases, SEC filings, and earnings call transcripts covering >1,800 publicly listed BioPharma companies

AI-assisted BioPharma Industry Research

Purpose-built to streamline the research and context-gathering process for BioPharma industry professionals

  • Full-text search

    Search across the full text of our document database with ease. Powerful controls allow additional filtering and sorting of results.

  • Grounded AI Answers

    ChatGPT-like Q&A grounded on our BioPharma-specific document library. In-line citations within answers link directly to primary sources.

  • Focus-able AI Answers

    Our AI knows what documents you are viewing and enables seamless summarization and analysis.

  • Only Biopharma

    Eliminate the noise - our database only contains documents published directly by biopharma companies

  • Powerful Keyboard shortcuts

    Navigate across documents with ease thanks to intuitive keyboard shortcuts.

  • Hop to the relevant passages in documents

    Navigate with ease to the relevant parts of documents based on your query.

Join the beta

Maven Bio's web application is currently in beta as we expand our database and feature set. To join the beta and start using the application, simply sign up below.